Pasithea Therapeutics Corp (KTTA)

Pasithea Therapeutics Corp (KTTA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $14M; returns 1 day -9.1%, 1 week -3.6%, 1 year -44.5%.

Pasithea Therapeutics Corp (KTTA) is a clinical-stage biotechnology company primarily focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. Its lead therapeutic candidate is PAS-004, a next-generation oral macrocyclic MEK inhibitor.

Groups KTTA belongs to

• Biotechnology
• Clinical Stage Biotech
• CNS Disorders
• R&D
• Rare Diseases
• Oncology
• Neuroscience
• Drug Discovery

KTTA financial model: income statement, cash flow and balance sheet